A new study shows that COVID-19 infection significantly increases the risk of exacerbation in patients with myasthenia gravis (MG).
Coërs, C., and Woolf, A. L., C. R. Cong. Médicins Aliénistes et Neurologistes, Liége, July 19–26, 1954; The Innervation of Muscle, 101 (Blackwell, Oxford, 1959).
So, I am baffled by my recent diagnosis of myasthenia gravis (MG)! Reading as much as possible for a clue, I found a (nonvalid) study stating that seniors who began taking statins mysteriously ...
Steroid-sparing agents reduce the risk of MG exacerbation post-COVID-19 infection ... the impact of COVID-19 on patients with myasthenia gravis, finding that although most patients did not ...
SAVANNAH, Ga. — Should patients with myasthenia gravis (MG) continue to undergo the traditional therapy of immunosuppression with drugs like corticosteroids and nonsteroidal agents? Or is it ...
There typically are periods when you may notice more symptoms (called an exacerbation) and periods when symptoms decrease or disappear (remission). Myasthenia gravis affecting multiple muscle ...
How Is Myasthenia Gravis Diagnosed? During a physical exam for myasthenia gravis, your health care provider may look for signs such as a droopy eyelid, difficulty holding your arms out at shoulder ...
Myasthenia gravis (MG) should be classified according ... generalized MG and for thymoma MG. In acute exacerbations including MG crisis, intravenous immunoglobulin and plasma exchange have good ...
Rituximab, developed by Genentech, is a chimeric murine-human monoclonal antibody against CD20 that depletes B cells. The protein CD20 plays an important role in the growth and differentiation of B ...
The nicotinic acetylcholine receptor (nAChR) is a major target of autoantibodies in myasthenia gravis (MG), an autoimmune disease that causes neuromuscular transmission dysfunction. Despite decades of ...